AHA 2025: amiloride matches spironolactone for resistant hypertension control
Both showed similar rates of blood pressure control, major adverse cardiovascular events, acute kidney injury and mortality over 12 months.
Both showed similar rates of blood pressure control, major adverse cardiovascular events, acute kidney injury and mortality over 12 months.
